Related Experiment Video
Updated: May 27, 2026
06:17
A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
Published on: May 22, 2018
Aβ(39-42) modulates Aβ oligomerization but not fibril formation
Megan Murray Gessel1, Chun Wu, Huiyuan Li
1Department of Chemistry and Biochemistry, University of California at Santa Barbara, Santa Barbara, California 93106, United States.
Biochemistry
|December 2, 2011
Summary
Amyloid beta (Aβ) C-terminal fragments (CTFs) like Aβ(39-42) inhibit Aβ42 toxicity by disrupting early oligomer formation. This peptide modulates assembly into nontoxic hetero-oligomers, not preventing fibril formation.
Area of Science:
- Neuroscience
- Biochemistry
- Molecular Biology
Background:
- Amyloid beta (Aβ) toxicity is implicated in neurodegenerative diseases.
- Certain C-terminal fragments (CTFs) of Aβ42 show potential as inhibitors of Aβ42 toxicity.
Purpose of the Study:
- To investigate the interaction between the Aβ(39-42) CTF and full-length Aβ.
- To elucidate the mechanism by which Aβ(39-42) affects Aβ assembly and toxicity.
Main Methods:
- Mass spectrometry to detect Aβ(39-42) binding.
- Molecular dynamics simulations to model Aβ42:Aβ(39-42) complex.
- Ion mobility-mass spectrometry (IM-MS) and electron microscopy to assess assembly disruption.
- Thioflavin T fluorescence to monitor fibril formation.
Main Results:
- Aβ(39-42) directly binds to Aβ monomers and various oligomers (n=2, 4, 6).
- Simulations reveal Aβ(39-42) binding at multiple sites on Aβ42, including the N-terminus.
- Aβ(39-42) prevents the formation of large Aβ42 oligomers and can remove them from solution.
- Aβ(39-42) does not inhibit amyloid fibril formation.
Conclusions:
- Aβ(39-42) inhibits Aβ42 toxicity by disrupting early soluble oligomer formation.
- The mechanism involves modulating assembly into nontoxic hetero-oligomers, distinct from preventing fibril formation.
- Oligomeric Aβ species, rather than fibrils, are likely the primary drivers of Aβ-induced toxicity.
More Related Videos
Related Concept Videos
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...